4ebp1 (pthr70)

A-1155463, a highly potent and selective BCL-XL inhibitor, shows picomolar binding affinity to BCL-XL, and >1000-fold weaker binding to BCL-2 and related proteins BCL-W(Ki=19 nM) and MCL-1(Ki>440 nM).

Forigerimod (IPP-201101), a potent CD4 T-cell modulator, is a 21-amino-acid fragment of the U1 small nuclear ribonucleoprotein 70 kDa, phosphorylated at Ser140, known for its ability to inhibit autophagy effectively. It has applications in researching autoimmune disorders, including systemic lupus erythematosus (SLE) [1] [2] [3] [4].

Forigerimod TFA (IPP-201101 TFA), a CD4 T-cell modulator, is a phosphorylated 21-amino-acid fragment derived from U1 small nuclear ribonucleoprotein 70 kDa, specifically at Ser140. It notably inhibits autophagy and is utilized in researching autoimmune disorders, including systemic lupus erythematosus (SLE) [1] [2] [3] [4].

Bivalirudin TFA, a synthetic 20-residue peptide, serves as a reversible inhibitor of thrombin. Its IC50 value highlights its target specificity in vitro, where, combined with Eptifibatide (8 mg mL) at a low concentration (70 ng mL), it significantly reduces platelet aggregation induced by thrombin (0.2 U mL) by approximately 90% [1]. The compound demonstrates no effect on thrombin generation assay (TGA) parameters up to 10 μmol L [2]. Additionally, it facilitates the binding of MPO to BAEC, leading to functional alterations such as increased NO consumption and enhanced MPO-mediated redox modifications [3]. In vivo studies reveal its efficacy in preventing the rise of antiheparin PF4 antibody IgG levels in rats, with significant findings from the toxicokinetic assessment signaling its safety profile at tested doses, although higher doses resulted in fatalities [4][5]. In clinical trials, its antithrombotic effects were explored, comparing it with alternatives like Ticagrelor and Clopidogrel in a Phase 4 study.